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Glioblastoma (GBM) is the most aggressive human brain tumor. Although several molecular subtypes of GBM are recognized, a robust
molecularprognosticmarkerhas yet tobe identified.Here,we report that the stemness regulator Sox2 is anew, clinically important target
of microRNA-21 (miR-21) in GBM, with implications for prognosis. Using the MiR-21–Sox2 regulatory axis, approximately half of all
GBM tumors present in the Cancer Genome Atlas (TCGA) and in-house patient databases can be mathematically classified into high
miR-21/low Sox2 (Class A) or low miR-21/high Sox2 (Class B) subtypes. This classification reflects phenotypically and molecularly
distinct characteristics and is not capturedby existing classifications. Supporting the distinct nature of the subtypes, gene set enrichment
analysis of the TCGA dataset predicted that Class A and Class B tumors were significantly involved in immune/inflammatory response
and in chromosomeorganizationandnervous systemdevelopment, respectively. PatientswithClassB tumorshad longeroverall survival
than thosewith Class A tumors. Analysis of both databases indicated that the Class A/Class B classification is a better predictor of patient
survival than currently usedparameters. Further,manipulation ofMiR-21–Sox2 levels in orthotopicmousemodels supported the longer
survival of the Class B subtype. The MiR-21–Sox2 association was also found in mouse neural stem cells and in the mouse brain at
different developmental stages, suggesting a role in normal development. Therefore, this mechanism-based classification suggests the
presence of two distinct populations of GBM patients with distinguishable phenotypic characteristics and clinical outcomes.
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Introduction
Gliomas are the most common type of malignant primary brain
tumor in adults, and glioblastoma (GBM) is the most common
and aggressive form of glioma (Gladson et al., 2010; Dunn et al.,
2012; Sanai and Berger, 2012; Huse et al., 2013; Louis et al., 2014;
Sturm et al., 2014; Lathia et al., 2015; Agnihotri and Zadeh, 2015;
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Significance Statement
Molecular profiling-based classification of glioblastoma (GBM) into four subtypes has substantially increased our understanding
of the biology of the disease and has pointed to the heterogeneous nature of GBM. However, this classification is not mechanism
based and its prognostic value is limited. Here, we identify a new mechanism in GBM (the miR-21–Sox2 axis) that can classify
50% of patients into two subtypes with distinct molecular, radiological, and pathological characteristics. Importantly, this
classification can predict patient survival better than the currently used parameters. Further, analysis of the miR-21-Sox2 rela-
tionship in mouse neural stem cells and in the mouse brain at different developmental stages indicates that miR-21 and Sox2 are
predominantly expressed in mutually exclusive patterns, suggesting a role in normal neural development.
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Aldape et al., 2015; Furnari et al., 2015), with an average survival
duration of 15 months. The standard therapies for GBM—sur-
gery, radiation therapy, and chemotherapy—are not very effec-
tive and the tumors generally relapse. Molecular analyses, the
generation of invaluable mouse models (Hambardzumyan et al.,
2011; Chen et al., 2012), and information derived from various
other sources have led to new therapeutic approaches for GBM
(Ahluwalia et al., 2010; Weller et al., 2012; Weller et al., 2013;
Cloughesy et al., 2014; Hamza et al., 2014; Wick et al., 2014;
Nabors et al., 2015). The molecular classification of GBM (Phil-
lips et al., 2006; Brennan et al., 2009; Noushmehr et al., 2010a;
Verhaak et al., 2010; Bastien et al., 2015) raised the hope that
patient survival could be easily and reliably predicted on the basis
of the classification system. However, although MGMT pro-
motermethylation (Hegi et al., 2005; Bady et al., 2012; Stupp and
Hegi, 2013; Wick et al., 2014) and IDH1 somatic mutation/G-
CIMP status (Noushmehr et al., 2010) can predict survival in
GBMpatients, a similar therapeutic regimen is still generally used
for all newly diagnosed GBM patients regardless of the patient’s
GBM subtype.Moreover, themain clinically accepted prognostic
factors are age, Karnofsky performance status, and degree of re-
section (Sanai and Berger, 2012; Hatiboglu et al., 2013) and there
is still no commonly implemented molecular marker.
MicroRNAs (miRNAs) are known to posttranscriptionally
regulate many genes by either destabilizing mRNA or blocking
translation and therefore play a critical role in normal develop-
ment, cancer, stress response, and other physiological states
(Singh et al., 2009; Gurtan and Sharp, 2013; Sheedy, 2015). Dys-
regulation ofmiRNA expression appears to be a common feature
in many cancers. MiRNA-21 (miR-21) is upregulated in many
cancers, including GBM (Møller et al., 2013; Sheedy, 2015).
However, expression of miR-21 in neural stem cells in transgenic
mice does not produce brain tumors (Huse et al., 2009;Medina et
al., 2010), suggesting a gap in our knowledge of the role ofmiR-21
in brain tumors. Here, we find that miR-21 destabilizes Sox2
expression.
Studies have indicated that GBM tumors consist of GBM
stem-like cells (GSCs) and have highlighted the roles of GSCs in
modulating the tumor microenvironment, neovascularization,
and tumor resistance to chemotherapy and radiation therapy
(Emmenegger and Wechsler-Reya, 2008; Dirks, 2010; Charles et
al., 2012; Sampetrean and Saya, 2013; Binda et al., 2014, Lathia et
al., 2015).However, it is unclear whether there are other cell types
in GBM tumors that might affect tumor biology and patient out-
comes. Here, we identify two phenotypically and molecularly
distinct cell types in GBM tumors that indicate different patient
prognoses.
Materials andMethods
MiR-21–Sox2 whole-genome screen. From the Cancer Genome Atlas
(TCGA) database, a log2- and median-centered mRNA and miRNA ex-
pression dataset consisting of 225 patients with primary untreated GBM
and Karnofsky performance scores70 was collated. The patients were
ranked according to miR-21 expression levels. The 20 patients with the
highest miR-21 expression levels were compared with the 20 with the
lowest miR-21 expression levels. Four patient datasets were generated;
each set had 10 patients with high miR-21 and 10 patients with low
miR-21. A whole-genome analysis by Comparative Marker Selection
(GenePattern suite, Broad Institute, Massachusetts Institute of Technol-
ogy, Cambridge,Massachusetts) revealed the top upregulated and down-
regulated genes in the high-miR-21 and low-miR-21 patients. Common
and significantly downregulated genes from each of the four sets were
compiled into a list of 69 genes. This list was then compared with the
predicted gene targets of miR-21 using miRWalk (Dweep et al., 2011)
and a final list of 29 genes inversely correlated with miR-21 and with at
least one predicted binding site remained. The genes were then ranked
according to both the predictive power of miR-21 binding and average
p-value across the four discovery sets. For visualization, a gene expression
heat map using the patient data analyzed was created using dChip soft-
ware (Fig. 1A).
Cell culture. Patient-derived GSCs were isolated from surgical speci-
mens of GBMpatients treated at TheUniversity of TexasM.D. Anderson
Cancer Center as described previously (Jiang et al., 2007; Kamal et al.,
2012). Briefly, GSCs were grown in DMEM F-12 medium (Invitrogen)
supplemented with 1:50 B27 (Invitrogen), 1:100 penicillin-streptomycin
(Invitrogen), 1:100 L-glutamine (Invitrogen), 20 ng/ml epidermal
growth factor (EGF) (Sigma-Aldrich), and 20 ng/ml basic fibroblast
growth factor (b-FGF) (Sigma-Aldrich). Cells were passaged every 3 or
4 d using enzymatic dissociation.
Neural stem cells (NSCs) were isolated from the cortices of wild-type
embryonic day 12 (E12)mouse embryos (Rietze andReynolds, 2006). All
of the mouse experiments were performed according to protocols ap-
proved by the Institutional Animal Care and Use Committee at M.D.
Anderson Cancer Center. Care was taken to remove the meninges and
other surrounding tissue. Briefly, the brains were dissected andmechan-
ically dissociated and then the cells were seeded in complete neurobasal
medium (Invitrogen) supplemented with 1:50 B27 (Invitrogen), 1:100
penicillin-streptomycin (Invitrogen), 1:100 L-glutamine (Invitrogen), 20
ng/ml EGF (Sigma-Aldrich), 20 ng/ml b-FGF (Sigma-Aldrich), and 20
g/ml heparin (Sigma-Aldrich) in ultra-low-attachment plates (Corn-
ing). Neurospheres were enzymatically dissociated into single cells using
Accutase (Sigma-Aldrich) once every 4–5 d. To induce differentiation of
E12 NSCs, cells were seeded on poly-L-ornithine-coated plates in differ-
entiating medium devoid of growth factors (EFG/FGF) and supple-
mented with 2% fetal bovine serum for 7 d.
In situ immunofluorescence. GSCs grown in chamber slides were fixed
with 4% paraformaldehyde for 15 min and washed 3 times with PBS.
Cells were then incubated in a prehybridization (pre-hyb) mixture (50%
formamide, 1 M NaCl, 1 Denhardt’s solution, 0.5 mg/ml yeast tRNA,
and 0.3% Triton X-100) for 2 h at 60°C. After pre-hyb, the cells were
incubated with biotin-labeled locked nucleic acid probes (Exiqon) at
60°C for 14–16 h in hybridizationmix (pre-hyb plus 25 nM probe). Next,
the cells were washed with 5  sodium chloride/sodium citrate buffer
(SSC), pH 7, for 5 min, 50% formamide in 1 SSC and 0.1% Tween 20
at hybridization temperature for 30 min, and 0.2  SSC for 10 min,
followed by 3 washes with PBS. Cells were incubated in fluorescein-
isothiocyante-avidin (1:500; Invitrogen) for 30 min. For the combined
immunofluorescence, the cells were blocked with a biotin-avidin kit
(Vector Laboratories) according to the manufacturer’s recommenda-
tions. Cells were blocked with 4% normal goat serum for 1 h and incu-
bated with the following primary antibodies overnight at 4°C: rabbit
anti-Sox-2 (1:50; Stemgent). The cells were then washed with PBS 3
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times, incubated with the corresponding secondary Alexa Fluor dyes for
1 h, washed twice with PBS, mounted with fluorescence-mounting me-
dium containing 4,6-diamidino-2-phenylindole (Vector Laboratories),
and photographed using a Nikon TE2000 controlled with MetaMorph
software (Molecular Devices).
The formalin-fixed, paraffin-embedded sectionswerewashedwith xy-
lene and rehydrated through decreasing ethanol concentrations. Antigen
retrieval was done at 100°C for 30 min in 10mM sodium citrate. Sections
were allowed to cool for 30 min and then in situ immunofluorescence or
immunofluorescence for Ki67 or TUNEL (Kamal et al., 2012) was per-
formed as described above.
Gain-of-function experiments. Stable overexpression of miR-21 was
achieved using custom-made lentiviruses overexpressing pre-miR-21 or
control vector (System Biosciences). In brief, 50,000 cells were plated on
24-well plates and allowed to recover for 3 h. Cells were incubated with
the pre-miR-21 lentivirus particles (multiplicity of infection  4) for
48 h. Cells were allowed to grow for 5 d and then sorted using green
fluorescent protein. Overexpression was confirmed using real-time PCR
analysis.
Luciferase assay. Stable GSC lines were generated using custom-made
lentiviruses against miR-21 (miRzip-21) or control vector lentiviruses
(control) from System Biosciences. MiRzip-21 or control cells were then
transfected with a double-luciferase 3-UTR reporter construct of hu-
man Sox2/Renilla control reporter (catalog #HmiT017628; GeneCo-
poeia) using the Amaxa electroporation system at a density of 1 g of
human Sox2 3-UTR construct per 1 107 cells” Transfected cells were
then incubated for 24 h and cell lysates were prepared. Firefly and Renilla
luciferase activity was measured by using the Dual-Glo luciferase assay
system according to the manufacturer’s instructions (Promega).
Quantitative real-time reverse transcription PCR. Total RNA was
isolated using the Trizol (Invitrogen)method according to themanufac-
turer’s instructions. MiRNA levels were estimated using the miRvana
quantitative reverse transcription (qRT)-PCR kit (Ambion) according to
the manufacturer’s instructions. For mRNA, cDNA synthesis was done
using aVerso cDNAkit (Thermo Scientific). Real-time PCR experiments
were done using an Applied Biosystems 7900 system.
Western blot analysis. Whole-cell lysates were prepared and30 g of
protein was separated on an SDS-PAGE gel (Pierce). Proteins were elec-
trophoretically transferred onto nitrocellulose membranes. The mem-
branes were probed with the following specific primary antibodies:
mouse anti-SOX2 (1:350; R&D Systems), rabbit anti-SOX2 (1:1000; Cell
Signaling Technology), andmouse anti-actin (1:10,000; Sigma-Aldrich),
followed by probing with IRDye-conjugated anti-mouse/anti-rabbit sec-
ondary antibodies (1:15,000; LI-COR) for 1 h. The blots were scanned
using the Odyssey infrared imaging system and quantified usingOdyssey
version 3.0 software.
Neurosphere assay. For GSCs, the neurosphere assay was performed as
described previously (Kamal et al., 2012). In brief, cells dissociated into
single-cell suspensions with 10 cells per well for self-renewal assay for
multiple generations or 100 cells per well self-renewal for single genera-
tion were seeded in 96-well plates and the number of neurospheres50
micron was counted after 15 d.
qRT-PCR for miR-21 and Sox2 in GBM patient samples. Tumor sam-
ples of patients with histologically confirmed GBM who were treated
at M.D. Anderson were obtained from the MDA Brain Tumor Center
tissue bank. A retrospective analysis of the patient charts was per-
formed to collect patient data such as age and overall survival. Sam-
ples were examined and dissected, if required, by a neuropathologist
(K.A.) to ensure purity of the tumor tissue. Total RNA was isolated
from the formalin-fixed paraffin-embedded tissues using the Epicen-
ter DNA and RNA isolation kit (Epicenter Biotechnologies) after
deparaffinization and proteinase K treatment of the paraffin-
embedded samples. Expression levels of miR-21 and Sox2 were quan-
Figure1. Sox2 is apotentially clinically relevantmiR-21 target inGBMandGBMpatients canbe classifiedbasedon the inverseMiR-21–Sox2 relationship.A, Heatmap showing inverse expression
pattern ofmiR-21 and its bioinformatically predicted targets in the TCGAGBMpatient database. Triangle on top showsmiR-21 expression levels (blue: low; red: high). The columnon the right shows
the corresponding predicted genes and ranks them according to the p-values for negative correlation tomiR-21 expression. The values on the right represent the number of algorithms that predict
the presence ofmiR-21-binding sites on the respectivemRNAs.B, C, Both TCGA andM.D. Anderson patients can be classified based onMiR-21–Sox2 status.B, Of the 353 primary untreated patient
samples withmRNA andmiRNA annotation present in the TCGA at time of analysis, 173 could be categorized using amedian cutoff method as either Class A (highmiR-21/low Sox2) or Class B (low
miR-21/high Sox2). Class C patients did not follow an inverse MiR-21–Sox2 correlation andwere left out of these data to reduce noise. C, Of the 69M.D. Anderson patients, 36 could be classified as
Class A or Class B usingmiR-21 and Sox2 expression levels determined from their GBM samples by qRT-PCR. The rest of the patients (Class C) did not fall into either of the two classes, similar to the
TCGA patients.
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tified using the relative threshold cycle method and normalized to
housekeeping gene EEF1A.
MiR-21–Sox2-based GBM classification using TCGA. TCGA
GBM level 1 expression data were obtained for mRNA expression
(http://cancergenome.nih.gov/). A robust multiarray analysis was
performed in R (R Project, http://www.r-project.org/). Among the
three probes available for Sox2, we chose the probe with the highest
variation and the highest mean to be representative of Sox2
(213721_at). For miR-21, level 2 Agilent data were downloaded and
the two highly correlated probes (Rsq  0.9) for miR-21 were aver-
aged. A total of 353 primary untreated patient samples with mRNA
and miRNA annotation were present in the TCGA at the time of
analysis. For each statistical analysis, the highest possible number of
patients was included, limited by pertinent annotation availability
and separation into high miR-21/low Sox2 and lowmiR-21/high Sox2
subtypes. The high miR-21/low Sox2 and low miR-21/high Sox2
groups were determined as specified below in the M.D. Anderson
patient set: the miR-21 and Sox2 expression data were stratified into
high miR-21/low Sox2 and low miR-21/high Sox2 using a median
expression cutoff. In this context, half of the samples were classified as
“high” and the other half were classified as “low” for bothmiR-21 and Sox2
independently. When classifying the patients on the basis of MiR-21–Sox2
status, 3 possible groups emerged: high miR-21/low Sox2 (Class A), low
miR-21/highSox2 (ClassB), andhighmiR-21/highSox2or lowmiR-21/low
Sox2 (Class C). Substratification was further performed for time to death,
vital status, age, Karnofsky performance status, and molecular GBM sub-
groups. Kaplan–Meier survival and Cox proportional hazards ratio were
calculated using Microsoft Excel 2010 and JMP version 9.01 statistical soft-
ware (SAS Institute).
MiR-21–Sox2-based GBM classification using RT-PCR. The expression
levels of miR-21 and Sox2 were normalized with EEF1a in the GBM
patient samples. Themedian values of miR-21 and Sox2 expression were
obtained. Samples above the median for each regulator were categorized
as “high” and samples below themedian were categorized as “low.” Sam-
ples were then stratified as Class A, Class B, or Class C. Median survival
and p-values were determined by Kaplan–Meier statistics using JMP 9.01
(SAS Institute).
TCGA phenotype analysis. Magnetic resonance images were obtained
from the Cancer Imaging Archive (http://cancerimagingarchive.net/)
and analyzed quantitatively for volume contrast enhancement and ne-
crosis as described previously (Zinn et al., 2011a). A total of 82 patients
were included in the analysis. Histopathology annotation for percentage
of necrosis was downloaded from the public TCGA data portal and
matched to our TCGA dataset. A total of 228 patients were included in
the analysis. Expression of TCGA stemness markers was calculated using
normalized TCGA mRNA expression for CD133, Nanog, and Nestin in
173 Class A and B patients. Mean necrosis and contrast volumes and SEs
for each Class (A–C) were calculated using JMP Pro version 9.01.
The methylation status of the MGMT promoter was predicted by
MGMT-STP27 (Bady et al., 2012). The raw DNA methylation datasets
(HM-450K) were obtained after Illumina preprocessing that included a
background correction with the R package minfi and the preprocessed
data were centered and normalized by probes, followed by unsupervised
hierarchical classification of the 1000 most variable probes (autosomes
only) using Ward’s algorithm and Euclidean distance to establish CpG
island methylator phenotype (CIMP) classification (green rectangle for
non-CIMP and red for CIMP), as defined in Bady et al. (2012). The R
statistical software package “survival” was used for the survival analysis.
Mouse orthotopic GBM models. Class B GSCs were treated with either
nontargeting shmiRNA (shNT) or shmiR-21. Clones were generated and
characterized as described previously (Kamal et al., 2012). These cells
were then used to assess the tumorigenic potential in vivo. Based on the
power analysis for each cell type, 8male nudemice 4–5weeks old (obtained
from the Department of Experimental Radiation Oncology atM.D. Ander-
son)wereused.The cells transducedwith vector alonewereused as controls.
Brain orthotopic tumormodelswere generated as described previously (Ka-
mal et al., 2012). Briefly, 50,000 cellswere implanted in a total volumeof 5l
into the right frontal lobes of themice. Prism version 6.01 software (Graph-
Pad) was used to generate survival curves.
Mouse orthotopic tumor characterization for cell proliferation using Ki67
assay. Paraffin sections were deparffinized by washing in xylene 3 times
for 5 min each. The sections were hydrated using gradient alcohols. An-
tigen retrieval was performed using citrate buffer and steaming for 20
min. The sections were allowed to cool down slowly for at least 90 min
before blocking with 5% goat serum followed by incubation with Ki67
(1:500, catalog #ab136912; Abcam) antibody for 1 h at room tempera-
ture. After washing twice with PBST, the sections were incubated with
secondary antibody followed by mounting with 4,6 diamino-2-
phenylindole (DAPI) (Vector Laboratories). Immunofluorescence sig-
nal was measured under a microscope. Six independent areas were
counted for quantification.
Mouse orthotopic tumor characterization for apoptosis by TUNEL assay.
TUNEL assay was performed according to manufacturer’s instructions
(catalog #11684817910; Roche). Briefly, the sections were deparffinized
and hydrated as described for the proliferation assay. After antigen re-
trieval using citrate buffer, the sections were cooled rapidly and blocked
in 20% goat serum, followed by the addition of TUNEL reactionmixture
and incubation for 1 h at 37°C in a humidified atmosphere. Sections were
washed with PBST followed by mounting medium with DAPI and posi-
tive cells were counted with a fluorescence microscope. Six independent
areas were counted for quantification.
Gene set enrichment analysis. For gene set enrichment analysis (GSEA),
TCGA human genome U133 array expression data for the 173 patients
withClassA (86 patients) orClass B (87 patients)GBMwere downloaded
through the TCGA data portal. The GSEA tool, developed by the Broad
Institute (http://www.broadinstitute.org/gsea) (Subramanian et al.,
2005), used a collection of 825 gene sets from the Molecular Signatures
Database (MSigDB) that were annotated for gene ontology biological
processes. The results were sorted according to the normalized enrich-
ment score (NES) and the false discovery rate (FDR). The significant
(FDR 0.01) gene sets with the top 10 positive and negative NES scores
were selected for unsupervised clustering analysis, which was performed
with R program language. The unsupervised clustering analysis classified
patients into groups based on the array expression datasets downloaded
from the TCGA databases. The  2 test level of significance of p  0.01
was used to confirm the classification of Class A and Class B tumors.
Results
MiR-21 targets the stemness regulator Sox2 in GBM
MiR-21 is believed to be expressed at high levels in GBM. To
understand the role of miR-21 in GBM, we first determined the
miR-21 levels in tumor samples from 279 patients using data
from TCGA and from 69 patients treated at M.D. Anderson. In
contrast to the common belief that all GBMs express relatively
high levels of miR-21, miR-21 was expressed at varying levels in
both experimental sets and miR-21 expression was associated
with survival differences that were not significant. We reasoned
that measurement of a parameter that reflects a biological
mechanism connected to miR-21 function, such as its critical
disease-specific gene target, would produce a biologically more
informative parameter. To identify a target of miR-21 that is
clinically relevant in GBM patients, we performed a whole-
genome screen using the TCGA. A total of 69 concordantly
downregulated genes in tumor samples with highmiR-21 expres-
sion were then cross-matched with predicted targets of miR-21
using miRWalk (Suh et al., 2007). The resulting 29 genes were
ranked according to the predictive power of miR-21 binding.
Sox2, which is required to maintain stem cell characteristics, or
“stemness,” in neural cells (Graham et al., 2003; Suh et al., 2007;
Shimozaki et al., 2012), was identified as the top predicted target
(5/8 algorithms) and one of the top inversely correlated genes
(p 0.01; Fig. 1A), suggesting that miR-21 suppresses Sox2 and
that the two have an inverse relationship in GBM.
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MiR-21–Sox2 status stratifies GBM tumors into two subtypes
To ascertain whether the MiR-21–Sox2 status can be used to
classify GBM tumors, we analyzed the TCGA dataset. Using the
median cutoff method, we identified two extreme subclasses that
corresponded to an inverse MiR-21–Sox2 relationship (Fig. 1B;
see Materials and Methods for details): progenitor-like, miR-
21High/Sox2Low (Class A) and stem-like, miR-21Low/Sox2High
(Class B). Class A and B tumors together comprised 50% of pa-
tients by default because of the method used. The remaining
patients (Class C) had tumors with miR-21 and Sox2 expression
that mathematically fell in between that of Class A and Class B
and could not be stratified accurately (see Discussion). This class
included either miR-21High/Sox2High (Class C1) or miR-21Low/
Sox2Low (Class C2) tumors. Therefore, themethod could identify
the two extremes on the spectrum as Class A and Class B. To
validate the TCGA results, we analyzed GBM tumor samples
fromM.D. Anderson patients (age 19–80 years).We determined
the miR-21 and Sox2 levels in the 69 formalin-fixed, paraffin-
embedded GBM samples using a simple qRT-PCR assay. Using
the median cutoff, we found that 36 of the 69 patients could be
categorized as either Class A or Class B, with the remaining pa-
tients falling into Class C (Fig. 1C). This ratio was similar to what
was observed in the TCGA dataset.
We then analyzed patient GBM specimens using a comple-
mentary in situ hybridization (to detect miR-21)/immunofluo-
rescence (to detect SOX2) assay. Examples of specimens
representing Class A and Class B are shown (Fig. 2A). For the
purposes of this work, we first concentrated on the miR-21-Sox2
mechanism-driven Class A and Class B tumors. Class C tumors
are described later.
MiR-21 mechanistically suppresses Sox2 expression and
MiR-21–Sox2 forms a regulatory axis
To obtain cells that could be experimentally manipulated, we
generated GSCs. To determine whether miR-21 negatively regu-
lates Sox2, we transduced a Class B-derived GSC line that ex-
presses low miR-21 and high Sox2 levels with lentiviral vectors
expressing the control vector or precursor miR-21 (pre-miR-21)
Figure 2. MiR-21 suppresses Sox2 expression in GBM. A, Two Class A and two Class B GBM tumor specimens were analyzed. Mir-21 expression was determined by in situ hybridization and Sox2
expression was determined by immunofluorescence. B, ExogenousmiR-21 decreased SOX2 protein levels in GSCs. Relative miR-21 levels determined by qRT-PCR (top) and SOX2 levels determined
byWestern blotting of GSCs transfectedwith either control or pre-miR-21 (bottom). Actinwas used as a control.C, Loss- andgain-of-function in luciferase reporter gene assays indicated thatmiR-21
suppresses Sox2 expression. Stable Class A GSC lines expressing antisense miR-21 (anti-miR-21) or control (anti-miR-NT) or Class B GSC lines expressing pre-miR-21 or control (pre-miR-NT) were
transfectedwith reporter plasmids encoding a luciferase cDNA containing the Sox2-specificmiR-21-binding site in its 3-UTR region and luciferase assayswere performed.MiR-21 knock-down cells
showed higher luciferase activity than the control cells. In contrast, miR-21-expressing cells showed lower luciferase activity than the corresponding control cells. D, miR-21 acts on the specific
miR-21-binding site present in Sox2 3-UTR and this activity can be rescued by amutant site. Stable Class B GSC lines expressing pre-miR-21 or control (NT) were transfected with an empty vector,
a reporter plasmid encoding a luciferase cDNA containing the Sox2-specific miR-21-binding site in its 3-UTR region, or a reporter plasmid encoding a luciferase cDNA containing a mutant
Sox2-specificmiR-21-binding site in its 3-UTR region. Cells were then processed and analyzed as described in (C) above. E, ExogenousmiR-21, which lowered Sox2 levels as described in (B) above,
caused decreased self-renewal as determined by neurosphere assay. F, Exogenous miR-21 decreased SOX2 protein levels in three additional GSC lines. Relative SOX2 levels were determined by
Western blotting of GSCs transfected with either control or pre-miR-21. Actin was used as a loading control.
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Figure 3. Class A versus Class B classification captures phenotypically and molecularly distinct tumors in TCGA dataset. A, Axial T1-weighted, contrast-enhanced MRI scans from four different
patients for each class demonstrate large ring-enhancingGBMtumorswith largevolumesofnecrosis in ClassA comparedwithClassB tumors.B, Analysis of contrast enhancement, necrosis, and total
tumor volume shows a significant difference between Classes A and B. C, Pathology score consisting of the amount of necrosis shows a significant difference between Classes A and B. D, E, Classes
A and B representmolecularly distinct tumors and are not captured by existingmolecular subtypes.D, Integrated view of genomic organization across 173 Class A or B GBMs. Shown is themutation
information for the genes IDH1, PDGFRA, EGFR, TP53, PTEN, and NF1; CIMP classification (green rectangle for non-CIMP and red for CIMP); methylation status of theMGMT promoter predicted by
MGMT-STP27 (blue for unmethylated and red formethylated); age; and sex. Right, Relationships between the descriptors and Class A/B tumors are assessed by 2 tests, with p-values computed by
Monte Carlo simulation. E, Expression of GBM-subtype-specific marker genes (Verhaak et al., 2010) in Class A and Class B tumors.
Figure 4. Differentially expressed genes in Class A and Class B tumors suggest distinct molecular subtypes. Shown is a comparison of 285 significantly expressed genes in Class A and Class B
tumors.
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and first validated that the exogenous pre-miR-21 caused an in-
crease in the endogenous miR-21 levels (Fig. 2B, top). We then
determined, using Western blotting assays, that the exogenous
pre-miR-21 decreased the SOX2 protein level (Fig. 2B, bottom).
To determine whether miR-21 binds to the 3-UTR of Sox2
mRNA, we constructed a Class A GSC stable cell line transduced
with either shRNA lentiviruses against miR-21 (shmiR-21) or
control vector (shNT) and a Class B GSC stable cell line trans-
duced with either lentiviruses expressing exogenous pre-miR-21
or its corresponding control. We then transfected the stable lines
with a dual reporter plasmid encoding a luciferase cDNA con-
taining the Sox2-specific miR-21-binding site in its 3-UTR re-
gion (Sox2 3-UTR) and cDNA containing an internal control
renilla luciferase and performed luciferase assays. Luciferase ac-
tivities were normalized to the internal control renilla luciferase.
We found higher luciferase activity under miR-21 knock-down
conditions and lower luciferase activity under miR-21 overex-
pression conditions in both Class A and Class B GSCs (Fig. 2C,
top: Class A, bottom: Class B).
To further confirm the specificity of the miR-21-binding site
present in the Sox2 3-UTR, we transfected a Class B GSC line
stably transduced with lentivirus expressing miR-21 (Fig. 2B) or
control with a dual reporter plasmid encoding a luciferase cDNA
containing no Sox2 3-UTR (empty vector), Sox2 3-UTR, or
Sox2 3-UTRmutated at themiR-21-binding site and an internal
control renilla luciferase and performed luciferase assays. Al-
though the luciferase activity of the nontargeting control- and
miR-21-transduced cells containing empty vector did not differ
Figure5. GSEAusingTGCAexpressiondata for ClassAandClass B tumors suggests distinctmolecular stratificationof ClassAandClass B tumors. Thegene setswerebasedon thebiological process
from gene ontology. A, Top 10 gene sets that are enriched in Class A and Class B tumors (FDR 0.01). B, C, GSEA diagrams showing that the gene sets related to chromosome organization and
biogenesis and development of the CNS and brain are enriched in Class B cases (B), whereas the gene sets related to immune system, immunological responses, and inflammation are enriched in
Class A cases (C).D, TCGA cases are clusteredbasedon theunsupervised clustering of enrichedgenes; 493genes from the20most enrichedgene sets inAwereused for theunbiased clustering. Based
on the columndendrogram, 173 TCGA patients (86 Class A and 87 Class B) are divided into two branches. Sixty-three Class A patients and seven Class B patients are grouped in the left branch. Eighty
Class B patients and 23 Class A are grouped in the right branch.
Table 1. Ingenuity pathway analysis for molecular and cellular functions between
Class A and Class B patients in the TCGA database
Molecular and cellular functions p-value No. of molecules
Class A
Cellular movement 1.00E-66 382
Cell-to-cell signaling and interaction 1.31E-55 350
Cell death 2.15E-51 478
Cellular growth and proliferation 8.67E-51 513
Antigen presentation 4.16E-34 205
Class B
Gene expression 1.70E-25 261
Cell cycle 4.00E-16 170
RNA posttranscriptional modification 1.32E-11 49
Cellular assembly and organization 7.55E-10 211
Cellular growth and proliferation 7.82E-10 275
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significantly, the Sox2 3-UTR vector produced lower luciferase
activity in the miR-21-transduced cells compared with the con-
trol (Fig. 2D). This lowered luciferase activity could be rescued by
the mutant Sox2 3-UTR construct (Fig. 2D). Together, these
results indicated that miR-21 interacts with the single, specific
binding site present on the Sox2 3-UTR.
To determine whether the suppression of Sox2 by miR-21
reflects Sox2’s biological function in regulating stemness, we took
the Class B cells transduced with lentiviruses expressing either
exogenous pre-miR-21 or its corresponding control, as described
in Figure 2B, and performed self-renewal assays. As shown in
Figure 2E, miR-21-mediated lowering of Sox2 expression caused
a corresponding decrease in the self-renewal capacity of these
cells.
Three GSC lines not used in the earlier experiments were
then transduced with lentiviruses expressing exogenous pre-
miR-21 or its corresponding nontargeting control and SOX2
protein levels were determined using Western blotting assays.
All of the GSC lines showed decreased levels of SOX2
upon expression of exogenous miR-21, confirming that the
MiR-21–Sox2 axis exists in additional GSC lines (Fig. 2F ).
Therefore, these results indicate that miR-21 functionally sup-
presses Sox2 in these cells.
Class A versus Class B classification delineates phenotypically
distinct GBM tumors
To determine whether Class A and B GBM tumors represent
distinct phenotypes, we performed quantitative MRI volumetric
Figure 6. Class A versus Class B classification is a stronger predictor of patient survival than currently used parameters. A, Kaplan–Meier survival analysis of TCGA patients with Class A and Class
B signatures showed shorter survival for Class A patients than Class B patientswith strong statistical significance.B, No statistically significant difference in survivalwas observedwhenmiR-21 alone
was considered. C, Statistically significant difference in survival was seen when Sox2 alone was considered, but it was less robust than the MiR-21–Sox2 axis. D, Kaplan–Meier survival analysis of
M.D. AndersonpatientswithClassAandClassBGBMshowedshorter survival for ClassApatients thanClassBpatients,with statistical significance.No statistically significantdifference in survivalwasobserved
when eithermiR-21 alone (E) or Sox2 alone (F )was considered.G,H, NeithermiR-19/PTEN (G) normiR-34/P53 (H )miR–mRNApairs show survival advantage among TCGAGBMpatients.
Table 2. Statistical calculations for TCGA Class A and Class B patient survival
Survival analysis Class A vs Class B
Test 2 p value
Log-rank 6.85 0.008
Wilcoxon 2.26 0.13
Survival time
Classification Median time (d) Mean time (d)
Class A 380 473
Class B 459 763
Proportional hazards ratio
Variable 2 p value
Class A vs B 4.3 0.038
KPS 2.89 0.089
AGE 0.28 0.59
CIMP status 0.07 0.79
MiR-21-Sox2 status is a strong and independently significant prognostic factor among Karnofsky performance
status, age, and CIMP status.
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analysis as described previously by our group (Zinn et al., 2011b).
The analysis demonstrated that the area of contrast enhancement
(p  0.03), amount of necrosis (p  0.04), and total tumor
volume (p  0.02) were significantly greater in Class A GBMs
than in Class B GBMs (Fig. 3A,B). When we analyzed the TCGA
histopathological patient data, we again found that Class A tu-
mors had significantly larger amounts of necrosis than Class B
tumors (Fig. 3C).
Class A versus Class B classification represents molecularly
distinct GBM tumors
We also analyzed the distribution patterns of the four known GBM
molecular subgroups (Verhaak et al., 2010) in our classification sys-
tem using the TCGA dataset. An integrated genomic view is shown
in Figure 3D. The detailed expression patterns of the subtype-
specific marker genes (Verhaak et al., 2010) in Class A and Class B
tumors are shown in Figure 3E. We found that neither Class A nor
Class B tumors aligned with the signature of any one subgroup;
instead, both Class A and Class B tumors included signatures of all
four subgroups, with a preponderance of the mesenchymal sub-
group inClass A and a preponderance of the classical and proneural
subgroups in Class B. Analysis of themutation status of well known
individual regulators ofGBMin these tumors indicated thatClassA,
compared with Class B, tumors had signifi-
cantly more NF1 mutation. The G-CIMP
phenotype, which belongs to the proneural
subgroup and correlateswith IDH1 somatic
mutation, is present in10% of GBM pa-
tients and predicts longer survival (Noush-
mehr et al., 2010). Our analysis indicated
that neitherG-CIMP (Bady et al., 2012) nor
IDH1mutationswere present inClass A tu-
mors; these mutations were significantly
more prevalent in Class B tumors, although
the actual number of mutations was low, as
expected. PDGFRA, EGFR, TP53, and
PTENmutations, as well as patient age and
sex, did not differ significantly between the
two classes of tumors.
To determine whether our classification
system also reflected distinct gene expres-
sion patterns, we performed a global gene
differential analysis using the TCGA data-
base. We used log2-fold change of 1 as a
cutoff and considered only those with ad-
justed p-values0.05. Comparison ofClass
A and Class B resulted in 285 genes. As
shown in the heat map (Fig. 4), such an
analysis showsdistinct gene expressionclus-
tering for Class A and Class B tumors.
We further interrogated the classifica-
tion system by performing GSEA using
TCGAexpressiondata forClassA andClass
B tumors using a collection of 825 gene sets
from the Molecular Signatures Database
that were annotated for gene ontology bio-
logical processes. The results were sorted
according to theNES and the FDR. The sig-
nificant (FDR 0.01) gene setswith the top
10 positive and negative NES scores are
shown in Figure 5A. Although Class B tu-
mors were significantly associated with
chromosomeorganizationandnervous sys-
tem development (Fig. 5B), Class A tumors were significantly asso-
ciatedwith immune/inflammatory response (Fig. 5C). A total of 493
geneswere further retrieved from the top 20 gene sets andwere used
in an unsupervised clustering analysis that classified patients into
groups based on the array expression datasets downloaded from the
TCGA database. The clustering results were visualized with a heat
map and dendrograms (Fig. 5D). The 2 test (p 0.01) provided
further confirmation for the distinct classification of Class A and
Class B tumors.
We also performed ingenuity pathway analysis of the genes ex-
pressed in Class A and Class B tumors present in TCGA database.
The results suggested cellular movement and cell-to-cell signaling
and interaction as some of the most significant canonical pathways
in Class A, but not Class B, tumors (Table 1). In contrast, gene
expression and cell cyclewere someof themost significant canonical
pathways in Class B, but not Class A, tumors. Therefore, analyses of
multiple molecular parameters as described above suggested that
Class A and Class B tumors represent molecularly distinct tumors.
Class A versus Class B classification is a stronger predictor of
patient survival than currently used parameters
To compare survival between Class A and B patients, we per-
formed a Kaplan–Meier analysis of the TCGA patient dataset
Figure 7. Decreased survival of mice harboring brain tumors derived from Class B GSCs expressing exogenous miR-21. Top,
Kaplan–Meier survival plots of mice harboring Class B GSCs expressing either pre-miR-NT control or pre-miR-21 (characterized
earlier in Figs. 2B). Expression of exogenous miR-21 lowered survival compared with control. Middle and bottom, GSCs plus
exogenous miR-21 intracranial tumors show higher cell proliferation (Ki67; middle) and lower apoptosis (TUNEL; bottom) com-
pared with control tumors.
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(N 173). The Class A patients had shorter survival than Class B
patients (median survival: 380 d for Class A vs 459 d for Class B;
p 0.0088; Fig. 6A, Table 2). The effect likelihood ratio showed
that MiR-21–Sox2 status was the strongest and only indepen-
dently significant prognostic factor (p  0.0381) among those
analyzed [Karnofsky performance status (p 0.0890), age (p
0.595), Table 2]. Importantly, although G-CIMP status predicts
survival in 10% of GBM patients (Noushmehr et al., 2010), it
had no significant survival prediction in our patient classification
(p  0.79; Table 2), suggesting that the survival difference seen
between Class A and Class B patients is independent of G-CIMP
status. Kaplan–Meier survival analysis showed that miR-21 by
itself did not significantly affect survival, even before corrections
(n  279; p  0.0761; Fig. 6B). Sox2 by itself was a significant
prognostic factor (n 279; p 0.0307; Fig. 6C). However, after
correcting for age and Karnofsky performance status, Sox2 lost
significance (p  0.0964) because of the stronger predictive
power of age (p 0.0003).
To validate the TCGA data analysis, we used M.D. Anderson
patient data. Kaplan–Meier results indicated that the MiR-21–
Sox2 combined signature was a significant prognostic indicator
(n 36; p 0.02; Fig. 6D), as opposed to miR-21 alone (Fig. 6E)
or Sox2 alone (Fig. 6F), among the M.D. Anderson patients.
When age and Karnofsky performance status were added to the
analysis, none of the parameters was significant, presumably be-
cause of the small number of patients.
We then analyzed other well characterized miRNA-mRNA
pairs such as miR-19/PTEN (n  156; p  0.52; Fig. 6G) and
miR-34/P53 (n 130; p 0.2; Fig. 6H) for survival advantage (Li
et al., 2009; Ernst et al., 2010). These results indicated that neither
of the pairs was statistically significant under similar settings,
further underscoring the novelty of the MiR-21–Sox2 axis.
To determine whether the impact ofMiR-21–Sox2 onGBMpa-
tient survival as determined in the TCGA and M.D. Anderson pa-
tient databases can be borne out by experimental manipulation, we
compared Class B GSC cells containing low miR-21 and high Sox2
levels with their isogenic counterparts containing exogenous pre-
miR-21. As characterized earlier (Fig. 2B), the transduced cells
showed increase expression of miR-21 and decreased expression of
SOX2.We then transplanted these cells into the brains of nudemice
using a screw-guided system that we had used previously (Kamal et
al., 2012) and performedKaplan–Meier survival analyses. As shown
inFigure7, top,overexpressionofmiR-21 inClassBGSCsdecreased
the survival of tumor-bearing mice, supporting the bioinformatic
results. Immunofluorescence analysis indicated that the addition of
exogenousmiR-21 to Class BGSCs increased cell proliferation (Fig.
7, middle) and decreased apoptosis (Fig. 7, bottom) in tumors and
was associated with decreased survival of tumor-bearingmice.
Classes A and B versus Class C tumors
Because the Class A and B tumor classifications were based on a
median cutoff value, we wanted to determine how the tumor char-
acteristics would be affected when Class C tumors were included in
the analyses.We first analyzedpatientGBMspecimens using in situ-
immunofluorescence analysis, as described in Figure 2A. Examples
of specimens representing Class C1 (miR-21High/Sox2High) and
Class C2 (miR-21Low/Sox2Low) are shown (Fig. 8A). As shown in
Figure 8B, the mutation analyses of various GBM regulators re-
mainedmostly similar towhatwas seenwhenonlyClassA andClass
B were considered.
We then performed quantitative MRI volumetric analysis of
Class A–C tumors. Because the classification was based on a me-
dian cutoff method and because Class C tumors fell in between
Classes A and B, one would expect that the median radiological
parameters of patients with Class C tumors would also fall be-
tweenClassesA andB. The analysis supported this prediction and
showed that the area of contrast enhancement, amount of necro-
sis, and total tumor volume for Class C tumors all fell between
those of Class A and B tumors (Fig. 8C).
We also wanted to determine what would happen when we
added Class C tumors to the patient survival prediction analysis.
Again, onewould expect that themedian survival of patients with
Class C tumors would fall between that of Classes A and B. Ka-
plan–Meier survival analysis, shown in Figure 8D, supported this
expectation. In addition, it also indicated that whereas the sur-
vival difference between Class A and B patients was highly signif-
icant (p 0.007), as expected, there was no significant difference
between the survival of Class A and Class C patients (p 0.203)
or between Class B and Class C patients (p 0.126). This obser-
vation further confirmed the prognostic value of the present clas-
sification schema.
MiR-21–Sox2 association is present in normal
neural development
Because cancer and normal development are intimately connected,
we wanted to determine whether the MiR-21–Sox2 axis is present
during normal development.We first generated neurospheres from
E12mouse embryonic brains. To confirm that miR-21mechanisti-
cally destabilizes Sox2 in NSCs, as in GSCs, we transfected pre-
miR-21 and the NT control into NSCs, cultured the cells under
neurosphere conditions, and analyzed the cells. Pre-miR-21 caused
an increase in the intracellular miR-21 levels (Fig. 9A) compared
with control, validating that the exogenous pre-miR-21 was pro-
cessed properly and converted intomiR-21 inside the cells.Western
blotting analysis (Fig. 9B) indicated that the additional miR-21,
compared with the NT control, caused a decrease in the Sox2 levels.
Therefore, miR-21 regulates Sox2 in NSCs.
We then determined the expression patterns of miR-21 and
Sox2 in these cells cultured under neurosphere and differentia-
tion conditions. An in situ hybridization (to detect miR-21)/im-
munofluorescence assay (to detect Sox2) analysis (Fig. 9C)
showed that NSCs under neurosphere conditions expressed
SOX2, a marker of NSCs, as expected, but did not express miR-
21. In contrast, miR-21 expression transiently appeared in cells
cultured under differentiation conditions for 1 d, in which Sox2
expression had diminished. Both miR-21 and Sox2 expressions
then drastically diminished in cells that were cultured for 7 d. To
confirm the differentiation status of these cells, we performed in
situ hybridization/immunofluorescence analyses of these cells to
examine the expression patterns of miR-21 and the early neuro-
nal differentiation marker neuronal b-tubulin. Neuronal
4
Figure 8. Comparison of Classes A and B versus Class C tumors in TCGA. A, In situ immuno-
fluorescenceanalysis of patientGBMspecimens representingClass C1andClass C2 (miR-21 High/
Sox2 High andmiR-21 Low/Sox2 Low, respectively).B, Integrated viewof genomic organization of
Classes A–C suggested that the mutation status of various GBM regulators remained mostly
similar compared with when Classes A and B alone were considered (Fig. 3D). C, Quantitative
MRI volumetric analysis of Class A–C tumors. The median radiological parameters (contrast
enhancement, amount of necrosis, and total tumor volume) of Class C tumors fell between
those of Class A and B tumors. D, Kaplan–Meier analysis also predicted the median survival of
Class C patients to fall between that of Class A patients and that of Class B patients. The signif-
icant survival difference was only observed between Class A and Class B patients ( p 0.007)
and not between Class A and Class C ( p 0.203) or between Class B and Class C ( p 0.126)
patients.
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b-tubulin was predominant only in cells
cultured under differentiation conditions
for 7 d (Fig. 9D).
Because bothClass A andClass BGSCs
could proliferate and give rise to neuro-
spheres, we wanted to determine whether
both high Sox2/low miR-21 NSCs (day 0)
and highmiR-21/low Sox2 differentiating
cells (day 1) could also proliferate. We
interrogated these cells with in situ hy-
bridization (miR-21) and immunofluo-
rescence (Ki67) analyses (Fig. 9E). As
shown, both neurospheres (day 0,miR-21
negative) and early differentiating (day 1,
miR-21 positive) cells, but not the differ-
entiated cells (day 7), are capable of cell
proliferation (Ki67 positive). Our results
are supported by earlier studies of normal
mouse brain development showing that
both NSCs and intermediate progenitors
can exhibit cell division (Ki67 positive).
Therefore, these results reinforced the ob-
servation that both Class A and Class B
GSCs are capable of generating neuro-
spheres, as was observed experimentally.
To ascertain whether the inverse ex-
pression pattern of miR-21 and Sox2 ex-
ists in vivo, we examined mouse sections
at E12, a stage of early neurogenesis, and
at E17, a later stage of neurogenesis, us-
ing in situ hybridization/immunofluores-
cence analysis (Fig. 10A,B, respectively).
As shown, E12 brain sections showed ro-
bust expression of Sox2 and very little ex-
pression of miR-21, whereas E17 brain
sections mostly showed very strong ex-
pression of miR-21 and weak expression
of Sox2. We then determined the miR21
and Sox2 expression patterns in adult
mouse brain sections (Fig. 10C). As
shown, miR-21 and Sox2 were expressed
in distinct cells. These results indicated
that miR-21 and Sox2 have predomi-
nantly mutually exclusive expression pat-
terns during development. Therefore,
together, the results described in this
section support the notion generated in
Figure 9. MiR-21 regulates Sox2 in NSCs and appears transiently during early differentiation in vitro. A, MiR-21 regulates Sox2
in mouse NSCs. E12 NSCs transfected with pre-miR-21 or pre-miR-NT control and analyzed by qRT-PCR confirmed that the
4
exogenous pre-miR-21 caused an increase in intracellular
miR-21. B, Western blotting analysis indicated that increased
miR-21 caused lowered SOX2 expression. C–E, In situ hybrid-
ization (miR-21)/immunofluorescence (protein marker) anal-
ysis of NSCs under neurosphere (day 0) and differentiation
(day 1 and day 7) conditions indicated that, whereas SOX2 is
mostly expressed in undifferentiated neurospheres, miR-21 is
mostly expressed transiently in early differentiating cells (C),
differentiationmarkerneuronal-tubulin (-tub) is predom-
inantly expressed in cells cultured for 7 d, as expected (D), and
both neurospheres (day 0,miR-21) and early differentiating
(day 1,miR-21	) cells, but not the differentiated (day 7) cells,
are capable of cell proliferation (cell proliferation marker
Ki67	) (E).
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the previous sections that Class B GSCs are more stem like,
whereas Class A GSCs are more progenitor like in nature.
Discussion
On the basis of our identification of Sox2 as a target of miR-21 in
GBM,wehave developed amiR21–Sox2-based classification system
that distinguishes miR-21Low/Sox2High (Class B) and miR-21High/
Sox2Low (ClassA) tumors.GSEApredicted oneof the enriched gene
sets of Class B tumor cells to be brain and CNS development. The
analogous high Sox2/lowmiR-21 neural stem cells during neuronal
differentiation support suchprediction. In contrast,GSEApredicted
one of the enriched gene sets of Class A tumor cells to be inflamma-
tory and immune response. The pro-inflammation gene PTX3,
which was associated with Class A tumors, is also a potential GBM
marker (Locatelli et al., 2013). Another such gene, LY86, is also a
potential inflammation response gene (Su et al., 2014). This is par-
ticularly significant because the inflammation/immune response
contributes significantly to theaggressivenessofGBMtumors (Glass
and Synowitz, 2014). Our findings that Class A tumors predict
poorer survival that Class B tumors is in agreement with this obser-
vation. Interestingly, Class A tumor cells appear to be similar to
neural progenitor cells during neuronal differentiation. Although a
bidirectional influence between inflammation/immunity and neu-
ral progenitor cells has been established (Merino et al., 2015) and
although miR-21 has been found to regulate inflammation in vari-
ous cell types (Tili et al., 2013; Sheedy, 2015), how the highmiR-21/
low Sox2 axis might mechanistically control inflammation/
immunity inClassAGBMtumors is notwell knownand thepresent
studyopens awindowon thispotentialmechanismofGBMbiology.
Compared with the known subtypes of GBM, Class A and
Class B tumors were found to be unique: neither class corre-
sponded completely with any known signatures of any specific
GBM subtype; instead, both classes contained a mixture of mo-
lecular signatures. Class B tumors contained a preponderance of
the proneural and classical signatures. The combined, context-
dependent effects of high levels of Sox2, a stemness regulator
(Shimozaki et al., 2012) and a marker of proneural GBM (Ver-
haak et al., 2010), and low levels of miR-21, a regulator of many
oncogenic functions in several cancers (Sheedy, 2015) and a
marker of mesenchymal tumors (Sintupisut et al., 2013), likely
contributed to the unique properties of Class B tumors. The high
Sox2 and low miR-21 levels also likely resulted in higher expres-
sion of EGFR, a marker of classical GBM tumors (Verhaak et al.,
2010), in these tumors. Class A tumors, which had preponder-
ance of the mesenchymal signature, likely resulted from the
context-dependent contribution of high miR-21 and low Sox2
levels. This contribution also extended to high expression ofNF1,
Figure10. MiR-21–Sox2 inverse association is present innormal neural development. In situhybridization (miR-21).immunofluorescence (SOX2) analysis of E12 (A), E17 (B), andadult (C)mouse
brain paraffin sections indicated that, whereas SOX2 was predominantly expressed in mouse brains at E12, miR-21 is predominantly expressed in mouse brains at E17 and miR-21 and SOX2 are
predominantly expressed in mutually exclusive patterns in adult brains.
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a marker of mesenchymal GBM tumors. How the simple MiR-
21–Sox2 axis might contribute mechanistically to the generation
of a complex GBM tumor biology, presumably in a context-
dependent manner, is yet to be determined.
Based on the brain transcriptome database (Cahoy et al.,
2008), Verhaak et al. (2010) found that each tumor subtype was
associated with a distinctive cellular lineage signature: proneural
(oligodendrocytic signature), classical (astrocytic signature),
neural (oligodendrocytic, astrocytic, and neural signatures), and
mesenchymal (cultured astroglial signature). As shown in Figure
4, we determined that 285 genes were differentially expressed in
Class A and Class B. A comparison of these genes with the lineage
markers suggested that most differentially expressed genes were
of astrocytic signature (77 genes); of these, 42 genes were overex-
pressed in Class B and 35 genes in Class A tumors. Overall anal-
ysis suggested that neither of the tumor types followed a strict
lineage. For example, the significant genes expressed in Class A
tumors included ARPC1B and NPC2 (oligodendrocytic signa-
ture), VAMP8 and CLIC1 (astrocytic signature), ITGA3 and
FHL2 (neural signature), and S100A11 and TAGLN (cultured
astroglial signature). Similarly, the significant genes expressed in
Class B tumors included CHD7 and GNG4 (oligodendrocytic
signature), BCAN and CSPG5 (astrocytic signature),MAPT and
CXXC4 (neural signature), and STMN2 (cultured astroglial sig-
nature). Overall, Class A tumors showed expression of greater
numbers of cultured astroglial signature genes than did Class B
tumors. This is perhaps to be expected because Class A tumors
had a greater preponderance of mesenchymal gene expression
than did Class B tumors (Fig. 3D,E). This lack of a clear associa-
tion between any of the four lineagemarkers and either Class A or
B tumors suggests that these are highly oncogenically evolved
tumors that have not retained the cellular lineage. Indeed, a lack
of association would be anticipated given the number of muta-
tions and alterations in these GBM tumors.
Our patient stratification based on theMiR-21–Sox2 axis also
discovered a third group (Class C), as one might expect from the
median cutoff method of analysis. Class C tumors exhibited high
miR-21 and high Sox2 levels or low miR-21 and low Sox2 levels.
The Class C tumors fell between Class A and Class B tumors, not
only in terms of their MiR-21–Sox2 ratio, but also in their bio-
logical properties. Class C tumorswere betweenClass A andClass
B with respect to both their phenotypic properties such as area of
contrast enhancement on MRI and amount of tumor necrosis
and patient survival. The mechanism driving the Class C tumors
and its significance to the GBM patient population remains un-
clear. Further studies in this direction would shed light on the
development of, not only Class C, but also Class A and Class B
tumors. Nonetheless, the presence of Class C tumors underscores
the distinct molecular and biological properties exhibited by the
Class A and Class B tumors.
The suppressive effect of miR-21 on Sox2 expression was also
seen recently in human mesenchymal stem cells, hair-follicle-
derived neural crest stem cells, and embryonic stem cells (Ni et
al., 2014; Trohatou et al., 2014; Singh et al., 2015). Interestingly,
an earlier study reported thatmiR-21 did not target Sox2 in either
neural cells or in GBM (Po˜lajeva et al., 2012), possibly because
those studies likely represented a specific subtype of cells that
excluded Class A and Class B cells. Our work suggests that the
MiR-21–Sox2 axis is likely to have significance for stem cells
other thanGSCs orNSCs. Because SOX2 is a positive regulator of
self-renewal and pluripotency for embryonic stem cells (ESCs),
one would expect that the presence of miR-21 would oppose
self-renewal and cause differentiation of ESCs. MiR-21 was first
identified through a comparison of differentiating (highmiR-21)
and undifferentiated (lowmiR-21)mouse ESCs (Houbaviy et al.,
2003), which supports the notion that miR-21 is associated with
suppression of stemness. We observed previously that miR-21
expression was indeed lower in undifferentiated E14Tg2a.4
mouse ESCs than in differentiating ESCs and found that the
forced expression of miR-21 in ESCs caused lowered rates of
self-renewal in these cells (Singh et al., 2008; Singh et al., 2012).
Importantly, miR-21-mediated regulation of ESCs is context de-
pendent (Buckley et al., 2009; Jørgensen et al., 2009a; Jørgensen et
al., 2009b; Singh et al., 2012; Singh et al., 2015), suggesting a
dynamic process in which various cell-intrinsic as well as cell-
extrinsic factors form part of an interconnected network. Finally,
because SOX2 is an induced pluripotent stem cell factor, our
work supports the finding that inhibition of miR-21 enhanced
induced pluripotent stem cell reprogramming efficiency (Yang et
al., 2011). Therefore, together, our results suggest that Sox2 and
miR-21 are key players in the stemness network of different cell
types affecting normal development and disease and that manip-
ulation of Sox2, miR-21, or both could be used to alter the out-
come of the network. Various approaches to target miR-21 in
GBM are already being pursued (Wang et al., 2015). Similarly,
immunotherapeutic approaches involving vaccination with
SOX2 peptides have also shown promise in a mouse model of
high-grade glioma, suggesting the feasibility of targeting SOX2
(Favaro et al., 2014).
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